Pharmaceuticals

Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Forecast to Hit $5.02 Billion by 2030 with 9.8% CAGR

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Across 2026–2030?

The market for calcitonin gene-related peptide (cgrp) inhibitors has shown significant growth in recent years. It is anticipated to increase from $3.14 billion in 2025 to $3.45 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.9%. This past growth can be attributed to a rising prevalence of migraine disorders, limitations associated with conventional migraine drugs, the growing clinical validation of the CGRP pathway, increased adoption by neurologists, and favorable reimbursement policies in developed markets.

The calcitonin gene-related peptide (cgrp) inhibitors market is projected to experience substantial expansion over the upcoming years, reaching $5.02 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.8%. This anticipated growth is fueled by factors such as a widening pool of chronic migraine patients, the ongoing development of oral CGRP inhibitors, a heightened need for sustained migraine prevention, enhanced patient compliance with specific treatments, and broadening market penetration in developing regions. Key developments expected during this period involve the increasing embrace of specialized migraine interventions, a growing focus on proactive migraine management, a stronger inclination towards non-opioid pain relief options, the proliferation of oral CGRP small molecule inhibitors, and improved recognition and diagnosis of chronic migraine.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24182&type=smp

What Primary Drivers Are Shaping The Development Of The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?

The rising incidence of migraine is anticipated to fuel expansion in the calcitonin gene-related peptide (CGRP) inhibitors market in the coming years. Migraine, characterized by severe headaches often involving pulsating pain on one side of the head, frequently presents with symptoms like nausea, vomiting, and heightened sensitivity to light and sound. The growing occurrence of migraine can be attributed to elevated stress levels, as sustained stress triggers specific neural pathways. Calcitonin gene-related peptide (CGRP) inhibitors play a crucial role in managing migraine by providing a precise, preventive approach suitable for both acute and long-term treatment plans. They effectively diminish the frequency and intensity of headaches through efficient CGRP receptor blockade, thereby enhancing patients’ quality of life and daily activities. For example, a report from January 2023 by the National Library of Medicine, a US-based health information institution, indicated that the global prevalence of migraine ranges from 14% to 15%, accounting for 4.9% of the total global disease burden. Consequently, the increasing prevalence of migraine is stimulating the growth of the calcitonin gene-related peptide (CGRP) inhibitors market.

What Segmentation Levels Are Considered In The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?

The calcitonin gene-related peptide (cgrp) inhibitors market covered in this report is segmented –

1) By Type Of Inhibitor: Monoclonal Antibodies, Small Molecules, Peptides

2) By Mechanism Of Action: Anti-Calcitonin Gene-Related Peptide (CGRP) Ligand, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist

3) By Route of Administration: Oral, Nasal, Intravenous

4) By Treatment: Preventive Migraine Treatment, Acute Migraine Treatment

5) By End User: Hospitals, Specialty Clinics, Mail Order Pharmacies, Retail Pharmacies

Subsegments:

1) By Monoclonal Antibodies: Erenumab (Aimovig), Eptinezumab (Vyepti), Fremanezumab (Ajovy), Galcanezumab (Emgality)

2) By Small Molecules: Ubrogepant, Rimegepant, Atogepant, Zavegepant

3) By Peptides: Calcitonin Gene-Related Peptide (CGRP) Antagonist Peptides, Modified Calcitonin Gene-Related Peptide (CGRP) Analogs, Intranasal Peptide Formulations, Peptide-Based Delivery Systems

What Trends Are Projected To Affect The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?

Major companies in the calcitonin gene-related peptide (CGRP) inhibitors market are prioritizing the development of innovative products to gain approvals, such as calcitonin gene-related peptide (CGRP) receptor antagonists, aiming to enhance the effectiveness of migraine treatment, expand therapeutic uses, and introduce more convenient administration methods like oral and intranasal formulations. A calcitonin gene-related peptide (CGRP) receptor antagonist is a medication that works by inhibiting the calcitonin gene-related peptide (CGRP) receptor to block pain signaling linked to migraine. For instance, in April 2023, AbbVie Inc., a US-based biotech company, received approval from the U.S. Food and Drug Administration (FDA) for QULIPTA (atogepant) to treat chronic migraine in adults. QULIPTA is an oral calcitonin gene-related peptide (CGRP) receptor antagonist that functions by blocking calcitonin gene-related peptide (CGRP) receptors, which are involved in the pathophysiology of migraine, thereby assisting in the prevention of migraine attacks.

Which Leading Firms Are Contributing To The Growth Of The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?

Major companies operating in the calcitonin gene-related peptide (cgrp) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Kissei Pharmaceutical Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., Shin Nippon Biomedical Laboratories Ltd., Sosei Group Corporation, Nuvie Bio Inc., Vaxxinity Inc., Acherx LLC, AfaSci Inc.

Read the full calcitonin gene-related peptide (cgrp) inhibitors market report here:

https://www.thebusinessresearchcompany.com/report/calcitonin-gene-related-peptide-cgrp-inhibitors-global-market-report

How Does The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Perform Across Major Global Regions?

North America was the largest region in the calcitonin gene-related peptide (CGRP) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin gene-related peptide (cgrp) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24182&type=smp

Browse Through More Reports Similar to the Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market 2026, By The Business Research Company

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Peptide Based Metabolic Disorders Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-based-metabolic-disorders-therapeutics-global-market-report

Cc Chemokine Receptor Type 5 Market Report 2026

https://www.thebusinessresearchcompany.com/report/cc-chemokine-receptor-type-5-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795